Press Releases

 
Press Releases
  Date Title and Summary View
Sep 25, 2003
Monrovia, CA – September 26, 2003 – Xencor, a drug discovery company, today reported the creation of a new class of inhibitors of TNF alpha, a critical protein involved in inflammatory disease. Scientists from Xencor used Protein Design Automation (PDA) technology, Xencor’s proprietary structure-based engineering platform, to d...
PDF
Sep 23, 2003
Monrovia, Calif.–Sept. 23, 2003–Technology Review, MIT’s magazine of innovation, announced in its October issue that Bassil Dahiyat, Ph.D., President and Chief Executive Officer of Xencor, a drug discovery company, has been named to its 2003 list of the world’s 100 Top Young Innovators. The TR100, chosen by the editors of...
PDF
Sep 23, 2003
Burnaby, British Columbia, Canada and Monrovia, California, United States – Chromos Molecular Systems Inc. (“Chromos“ TSX: CHR) and Xencor announced today that they have entered into a non-exclusive research license agreement to develop cell lines that express Xencor’s monoclonal antibodies and other recombinant protein p...
PDF
Oct 9, 2002
Monrovia, CA – October 9, 2002 – Xencor today announced that it has been awarded a $2 million Advanced Technology Program grant from the National Institute of Standards and Technology to support the discovery of safer and more effective protein therapeutics. The three-year federal grant, titled “Rational Design of Non-immunogen...
PDF
Jun 17, 2002
(BW Healthwire)–June 17, 2002—Monrovia, CA – Xencor today announced that it has reached a major milestone in its research agreement with Syngenta’s (NYSE: SYT) Torrey Mesa Research Institute (TMRI). In just six months, half the time agreed upon, Xencor has created and delivered optimized protein candidates that will enabl...
PDF
Jun 4, 2002
(BW Healthwire)–June 04, 2002—Xencor’s Vice President, Discovery Technologies, Robert Pacifici, Ph.D., Presents at BIO 2002, June 10 at 10:30 a.m.-12:00 p.m. in room 701A. Monrovia, CA – Xencor, a drug discovery company focused on protein optimization and chemical genomics, today announced that Robert Pacifici, Ph...
PDF
May 29, 2002
Monrovia, CA – May 29, 2002 – Xencor, a drug discovery company, today reported results from two protein optimization programs on key pharmaceutical proteins, recombinant human growth hormone (hGH) and granulocyte-colony stimulating factor (G-CSF). Using its proprietary Protein Design AutomationTM (PDATM) technology, Xencor computatio...
PDF
Apr 18, 2002
Monrovia, CA – April 18, 2002 – Xencor, a drug discovery company focused on chemical genomics and protein optimization, today announced that Bassil Dahiyat, Ph.D., President and CEO, will chair the "Chemical Genomics-Linking Drug Activity with Protein Function" panel at the 10th annual CALBIOsummit in San Diego, CA, April 22 from 1:4...
PDF
Mar 11, 2002
Monrovia, CA – March 11, 2002 – Xencor today announced that it has exclusively licensed a patent from the Johns Hopkins University School of Medicine (US #6,190,856 B1) entitled, “Methods of Detection Utilizing Modified Bacteriophage,“ expanding the Company’s patent estate for its proprietary chemical genomics platf...
PDF
Feb 20, 2002
(BW Healthwire)–February 20, 2002—Monrovia, CA – February 20, 2002 – Xencor today announced that it has signed licensing agreements with the California Institute of Technology and Pennsylvania State University to further expand its proprietary Protein Design Automation™ (PDA...
PDF
Page: FirstPrevious ...
18
NextLast
Xencor © Copyright 2017